HOOKIPA Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Cash & Equivalents	117.1	113.03	66.49	142.74	113.15	48.58	61.36
Cash & Cash Equivalents	117.1	113.03	66.49	142.74	113.15	48.58	61.36
Cash Growth	3.60%	70.00%	-53.42%	26.15%	132.92%	-20.83%	-
Receivables	19.27	22.01	21.17	20.66	9.73	7.25	6.52
Other Current Assets	10.75	12.16	14.48	8.1	5.14	6.48	2.08
Total Current Assets	147.12	147.2	102.14	171.5	128.02	62.31	69.96
Property, Plant & Equipment	13.22	21.98	22.12	13.97	14.6	4.34	3.58
Long-Term Investments	0.43	0.42	0.43	0.43	0.42	0	0
Other Long-Term Assets	0.58	0.86	1.37	1.91	0.7	1.6	0.2
Total Long-Term Assets	14.22	23.26	23.91	16.31	15.73	5.94	3.77
Total Assets	161.34	170.45	126.05	187.82	143.75	68.25	73.73
Accounts Payable	12.5	5.49	8.76	8.01	0.94	3.66	1.48
Deferred Revenue	34.31	41.35	5.56	4.53	3.66	8.28	0
Current Debt	2.76	3.28	4.47	2	1.81	0	0
Other Current Liabilities	-7.57	-14.49	8.86	6.6	8.33	2.76	2.56
Total Current Liabilities	41.99	35.63	27.65	21.14	14.76	14.7	4.04
Long-Term Debt	3.8	3.22	6.13	8.36	8.79	4.39	3.74
Other Long-Term Liabilities	25.69	29.08	2.67	2.2	2.31	4.77	3.84
Total Long-Term Liabilities	29.49	32.31	8.8	10.55	11.09	9.16	7.58
Total Liabilities	71.48	67.94	36.45	31.69	25.85	23.85	11.61
Total Debt	6.56	6.5	10.6	10.35	10.6	4.39	3.74
Debt Growth	0.86%	-38.67%	2.41%	-2.31%	141.33%	17.50%	-
Retained Earnings	-369.26	-287.68	-222.77	-147.1	-103.02	-59.98	-43.75
Comprehensive Income	-7.93	-7.16	-4.78	-6.07	-4.65	-3.72	-1.36
Shareholders' Equity	89.86	102.52	89.59	156.12	117.9	-60.38	-42.66
Net Cash / Debt	110.54	106.52	55.88	132.39	102.55	44.19	57.62
Net Cash / Debt Growth	3.77%	90.62%	-57.79%	29.09%	132.08%	-23.32%	-
Net Cash Per Share	-	-	-	-	5.74	48.33	63.20
Working Capital	105.13	111.56	74.48	150.36	113.26	47.62	65.92
Book Value Per Share	1.07	1.87	2.99	6.08	6.60	-66.03	-46.78

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).